-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewAcute Ischemic Stroke – Drugs In Development, 2024
Empower your strategies with our Acute Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. An acute ischemic stroke occurs when a clot blocks a brain blood vessel, depriving it of oxygen. Symptoms, like numbness, confusion, or difficulty speaking, arise suddenly. Immediate medical attention is crucial. Treatment focuses on restoring blood flow, often with clot-dissolving drugs or a thrombectomy. Recovery varies; rehabilitation helps regain lost abilities. Lifestyle changes and medication may prevent future strokes. Early recognition...
-
Product Insights
NewVenous Thromboembolism – Drugs In Development, 2024
Empower your strategies with our Venous Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. Venous thromboembolism (VTE) is a condition that occurs when a blood clot forms in a vein and blocks the blood flow. VTE can affect the deep veins of the legs or arms (deep vein thrombosis, or DVT) or the lungs (pulmonary embolism, or PE). VTE can cause serious complications such as tissue damage, organ failure, or death. VTE can be provoked by...
-
Product Insights
NewVenous (Vein) Thrombosis – Drugs In Development, 2024
Empower your strategies with our Venous (Vein) Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Venous thromboembolism (VTE) is a condition characterized by the formation of blood clots in veins, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT typically manifests in deep veins, commonly in the lower leg, thigh, or pelvis, and can extend to the arms, particularly with intravenous central lines. Pulmonary embolism occurs when a detached clot travels to the lungs. With...
-
Product Insights
NewThromboembolism – Drugs In Development, 2024
Empower your strategies with our Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. A thromboembolism occurs when a blood clot (thrombus) break and travels in the bloodstream. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery. The Thromboembolism drugs in development market research report provide comprehensive information...
-
Product Insights
NewThrombosis – Drugs In Development, 2024
Empower your strategies with our Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a...
-
Product Insights
NewDeep Vein Thrombosis (DVT) – Drugs In Development, 2024
Empower your strategies with our Deep Vein Thrombosis (DVT) – Drugs In Development, 2024 report and make more profitable business decisions. Deep vein thrombosis (DVT) is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema), and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a...
-
Product Insights
NewPulmonary Embolism – Drugs In Development, 2024
Empower your strategies with our Pulmonary Embolism – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat, and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics. The Pulmonary Embolism drugs in development market research...
-
Product Insights
NewIschemic Stroke – Drugs In Development, 2024
Empower your strategies with our Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexucabtagene Autoleucel in Burkitt Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexucabtagene autoleucel in Burkitt Lymphoma Drug Details: Brexucabtagene Autoleucel (Tecartus) is a CD19-directed genetically...